Before you can access ASH's online program, you must agree to the following:
Last updated January 16, 2009. Please note that this site represents the latest program changes
and differs from the print version in some details.
Start | Author Index

721.O1.6 Clinical Transplantation - Transplantation Regimen Toxicities and Engraftment 1

Sunday, December 7, 2008: 4:30 PM-6:00 PM
2009-2011-2022-2024 - West (Moscone Center)
Moderators:
Arnold Ganser, MD, PhD and Thomas J. Nevill, MD, FRCPC
4:30 PM
49
Treatment-Related Mortality  and Relapse Rate from Time of Initiation of Post-Remission Therapy for Patients Receiving Allogeneic Transplantation, Autologous Transplantation or Intensive Chemotherapy: A Report from the Eastern Cooperative Oncology Group (ECOG)

Jacob M. Rowe, MD1, Zhuoxin Sun, Ph.D2*, Peter A. Cassileth, MD3, Frederick R. Appelbaum, MD4, Peter H. Wiernik, MD5, Hillard M Lazarus, MD6*, Karl G. Blume, MD7, Hugo F. Fernandez, MD8, Mark R. Litzow, MD9 and Martin S Tallman10

1Hematology and Bone Marrow Transplantation, Rambam Health Care Campus and Technion, Israel Institute of Technology, Haifa, Israel., Haifa, Israel
2Biostatistics & Computational Biology, Dana-Farber Cancer Institute, Boston, MA
3Univ. of Miami Sylvester Cancer Ctr., Miami, FL
4Fred Hutchinson Cancer Research Center, University of Washington School of Medicine, Seattle, WA
5New York Medical College, Our Lady of Mercy Cancer Center, Bronx, NY
6Ireland Cancer Center, University Hospitals of Cleveland, Cleveland, OH
7Stanford Univ. Medical Ctr., Stanford, CA
8H. Lee Moffitt Cancer Ctr. & Res. Inst., Tampa, FL
9Mayo Clinic, Rochester, MN
10Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL
4:45 PM
50
Polyoma (BK) Viruria Prior to Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) from Donors Other Than Matched Siblings: A Prospective Evaluation of Hemorrhagic Cystitis (HC) IncidenceClinically Relevant Abstract

Leandro de Padua Silva1, Poliana Patah1*, Rima M. Saliba1*, Nicholas A. Szewczyk1*, Lisa Gilman1*, Alison Gulbis1*, Joyce Neumann1*, Julia Walker1*, Demetrios Petropoulos1*, Rocco LaSala2*, Kashif Ali Shaz Mir1*, Yago Nieto1*, Issa Khouri1*, Sergio Giralt1*, Richard E. Champlin1* and Marcos De Lima1*

1Department of Stem Cell Transplantation & Cell Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX
2Division of Pathology & Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
5:00 PM
51
Obesity Does Not Preclude Safe and Effective Myeloablative Hematopoietic Cell Transplantation (HCT) for Acute Myeloid Leukemia (AML) in AdultsClinically Relevant Abstract

Willis H. Navarro, MD1, Manza- A Agovi, MPH2*, Brent Logan, PhD2*, Andrea Bacigalupo, MD3*, Karen K Ballen, MD4, Brian J. Bolwell, MD5, Haydar Frangoul, MD6, Vikas Gupta, MD, MRCP, MRCPath7, Theresa Hahn, PhD8, Mark Juckett, MD9, Hillard M. Lazarus, MD10, Mark R. Litzow, MD11, Jane Liesveld, MD8*, Jan Moreb, MD12*, David Marks, MD, PhD13, Philip L. McCarthy, MD8 and J. Douglas Rizzo, MD, MS2

1National Marrow Donor Program, Minneapolis, MN
2Medical College of Wisconsin, Center for International Blood and Marrow Transplant Research, Milwaukee, WI
3San Martino Hospital, Genoa, Italy
4Massachusetts General Hospital, Boston, MA
5Cleveland Clinic, Cleveland, OH
6Vanderbilt University Medical Center, Nashville, TN
7Princess Margaret Hospital, Toronto, ON, Canada
8Roswell Park Cancer Institute, Buffalo, NY
9Univ. of WI Hospitals & Clinic, Madison, WI
10University Hospitals Case Medical Center, Cleveland, OH
11Mayo Clinic, Rochester, MN
12Shands Hospital, Gainesville, FL
13United Bristol Healthcare Trust., Bristol, United Kingdom
5:15 PM
52
Clinical and Genetic Factors Underlying Acute Bone Mineral Density Loss by 100 Days after Blood and Marrow Transplantation: A Potential Early Regimen-Related Complication

Theresa Hahn, PhD, Song Yao*, Shannon Smiley*, Kathleen West*, Minoo Battiwalla*, Dominick Lamonica* and Philip L McCarthy, Jr*

Roswell Park Cancer Institute, Buffalo, NY
5:30 PM
53
Treatment-Related Mortality in Patients with AL Amyloidosis Undergoing High-Dose Melphalan and Stem Cell Transplantation: Trend Over the Past 14 Years at a Single InstitutionClinically Relevant Abstract

Vaishali Sanchorawala, MD, Martha Skinner*, Kathleen T. Finn*, Karen Quillen* and David C. Seldin*

Boston Univ. Med. Ctr., Boston, MA
5:45 PM
54
Darbepoetin-Alfa and I.V. Iron Administration after Autologous Hematopoietic Stem Cell Transplantation : A Prospective Randomized Multicenter TrialClinically Relevant Abstract

Yves Beguin1, Johan Maertens2*, Bernard De Prijck3*, Rik Schots, MD4*, Pascale Frere1*, Christophe Bonnet1*, Kaoutar Hafraoui1*, Evelyne Willems1*, Gaetan Vanstraelen1*, Marie Lejeune1*, Koen Theunissen5*, Georges Fillet1 and Frederic Baron1*

1ULg, Liege, Belgium
2Clinical Hematology Division, Hospital de Sant Pau, Barcelona, Spain
3CHR La Citadelle, Liege, Belgium
4Myeloma Study Group, Belgian Hematological Society, Brussels, Belgium
5KUL, Leuven, Belgium
See more of: Oral and Poster Abstracts
<< Previous Session | Next Session >>

*signifies non-member of ASH